Government Restricts Manufacture, Sale and Distribution of Fixed Dose Combinations Containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride for Use in Children Below Four Years
In this note
1. At a Glance
- Government of India (Ministry of Health & Family Welfare/CDSCO) has restricted manufacture, sale and distribution of Fixed Dose Combinations (FDCs) of Chlorpheniramine Maleate + Phenylephrine Hydrochloride for children below four years of age [1].
- Action taken under Section 26A of the Drugs and Cosmetics Act, 1940, empowering the Centre to prohibit drugs deemed risky to public health [1].
- Relevant for UPSC as a recurring pattern: drug safety regulation, FDC governance, and CDSCO's regulatory role — a live issue given repeated cough-syrup child-death controversies (domestic and export-linked) [1].
- Mandatory warning label required: "This Fixed Dose Combination shall not be used in children below four years of age" on packaging, label and promotional material [1].
2. Why in the News
- Government notification restricting this FDC reported around August 2026, based on recommendations of the Subject Expert Committee (SEC) and the Drugs Technical Advisory Board (DTAB) [1].
- Follows earlier SEC recommendation of 6 June 2023 that this FDC (chlorpheniramine maleate 2mg + phenylephrine HCl 5mg drops) should not be used in children below four years, after CDSCO flagged it as an unapproved infant formulation [1].
- Broader context: global reports of child deaths (at least 141 worldwide) linked to contaminated/misused cough syrups prompted heightened scrutiny of pediatric FDCs [1].
3. Background & Evolution
- CDSCO (Central Drugs Standard Control Organisation) is India's national drug regulatory body under the Ministry of Health & Family Welfare, responsible for approval of new drugs, clinical trials, and FDC regulation.
- FDCs combining two or more active pharmaceutical ingredients require specific approval; many older cold/cough FDCs (like this one) were sold historically without formal safety review for infants.
- 6 June 2023: SEC flags the chlorpheniramine maleate + phenylephrine HCl combination as an unapproved formulation for infants and recommends restriction plus warning labels [1].
- 2026: Formal government restriction notified, invoking Section 26A of the Drugs and Cosmetics Act, 1940, prohibiting use in children below four years, following DTAB endorsement [1].
- Fits a pattern of periodic FDC bans in India (e.g., earlier bans on hundreds of irrational FDCs) aimed at curbing use of unscientific/unsafe drug combinations.
4. Core Static Facts
| Item | Detail |
|---|---|
| Drug combination | Chlorpheniramine Maleate (antihistamine) + Phenylephrine Hydrochloride (decongestant) |
| Restriction | Manufacture, sale, distribution banned for children below 4 years |
| Legal provision | Section 26A, Drugs and Cosmetics Act, 1940 [1] |
| Recommending bodies | Subject Expert Committee (SEC); Drugs Technical Advisory Board (DTAB) [1] |
| Regulator | CDSCO, under Ministry of Health & Family Welfare [1] |
| Mandatory label | "This Fixed Dose Combination shall not be used in children below four years of age" [1] |
| Trigger date (SEC recommendation) | 6 June 2023 [1] |
| Notification timeframe | 2026 [1] |
5. Multi-Dimensional Analysis
Social
- Directly protects infants/toddlers, a vulnerable group with limited capacity for informed consent in medication use [1].
- Public health messaging challenge: parents/pharmacists must be made aware of the new warning to prevent continued off-label use.
Legal/Constitutional
- Exercise of executive rule-making power under Section 26A of the Drugs and Cosmetics Act, 1940 — a Central Act enabling prohibition of drugs "essential to meet the requirement... injurious to health" [1].
- Illustrates Centre-driven regulatory federalism in pharmaceutical safety (state drug controllers implement Central Government-notified restrictions).
Scientific/Technological
- Reflects evidence-based regulatory review: expert committees (SEC, DTAB) evaluate pharmacological risk-benefit specifically for pediatric age groups [1].
- Highlights risks of extrapolating adult-dose pharmacology to infants without dedicated pediatric trials.
Administrative/Governance
- Tests CDSCO's post-market surveillance and enforcement capacity — labeling mandates require monitoring compliance across thousands of small manufacturers.
- Enforcement gaps (state drug inspectors, informal retail sale) remain a recurring criticism in India's pharma regulatory ecosystem.
Ethical
- Balances industry/commercial interests (established, widely-sold cold remedy) against child safety — precautionary principle in drug regulation.
6. Recent Developments (last 12-18 months)
- June 2023: SEC recommendation flagging the FDC as unsafe/unapproved for infants [1].
- 2026: Government formally restricts manufacture, sale and distribution of the FDC for children below four years, mandating warning labels, following DTAB review [1].
7. Prelims Hooks
- The restricted FDC combines Chlorpheniramine Maleate (antihistamine) and Phenylephrine Hydrochloride (decongestant) [1].
- Restriction applies to children below four years of age [1].
- Legal basis: Section 26A, Drugs and Cosmetics Act, 1940 [1].
- Regulator involved: CDSCO (Central Drugs Standard Control Organisation) [1].
- Advisory bodies: Subject Expert Committee (SEC) and Drugs Technical Advisory Board (DTAB) [1].
- SEC's original recommendation on this FDC dates to 6 June 2023 [1].
- Mandatory warning: manufacturers must state the FDC "shall not be used in children below four years of age" on label, package insert, and promotional literature [1].
- Ministry involved: Ministry of Health and Family Welfare [1].
- Section 26A empowers the Central Government to prohibit manufacture/sale of any drug in public interest.
- CDSCO functions under the Directorate General of Health Services, Ministry of Health & Family Welfare.
8. Mains Relevance
- GS-II: Health — Government policies and interventions for issues relating to health; Governance — Statutory, regulatory bodies (CDSCO, DTAB).
- GS-III: Science & Technology — issues relating to drug safety, pharmaceutical regulation.
- Possible question stems: 1. "Examine the regulatory mechanism for approval and restriction of Fixed Dose Combinations (FDCs) in India. Discuss recent measures taken to protect children from unsafe drug combinations." (GS-II/III) 2. "The recurring controversies around child deaths linked to cough syrups reveal gaps in India's pharmaceutical regulatory architecture. Critically examine." (GS-II) 3. "Discuss the role and powers of the Drugs Technical Advisory Board and Section 26A of the Drugs and Cosmetics Act, 1940 in safeguarding public health." (GS-II)
9. Related Topics to Study Next
- Drugs and Cosmetics Act, 1940 & Rules, 1945 — foundational legal framework for drug regulation in India.
- CDSCO and state drug regulatory structure — Centre-state division in pharma enforcement.
- New Drugs and Clinical Trials Rules, 2019 — governs clinical trial approvals, relevant to pediatric drug testing.
- Irrational FDC bans (2016, 2018) — earlier Supreme Court-linked bans on hundreds of FDCs, useful comparative precedent.
- National Pharmaceutical Pricing Authority (NPPA) — related but distinct regulatory body on drug pricing.
- WHO Essential Medicines List & pediatric formulations guidance — international benchmark, Tier 2 source (who.int).
- Global cough syrup deaths (Gambia, Uzbekistan cases) — comparative regulatory failure cases relevant for international drug safety discourse.
- Jan Aushadhi / PMBJP scheme — links to broader affordable/generic medicine access debates.
10. Common Errors / Trap Areas
- Confusing CDSCO (Central regulator, under Ministry of Health & Family Welfare) with NPPA (pricing regulator) — different mandates.
- Mixing up the SEC (technical/scientific evaluation) with DTAB (statutory advisory board under the Act) — both are involved but at different stages.
- Assuming the ban is a total ban on the drug combination — it is age-specific (below 4 years), not a blanket prohibition.
- Wrong Act/Section: this restriction is under the Drugs and Cosmetics Act, 1940 (Section 26A), not the Pharmacy Act or NDPS Act.
- Assuming this is the first-ever FDC restriction in India — it follows a longer history of FDC bans (2016, 2018) which aspirants often forget to contextualize.